Loading
A phase 2 trial of Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Oxaliplatin in advanced solid tumours, run by Mirati Therapeutics Inc., now recruiting.
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies is a phase 2 interventional study registered as NCT07415031 by Mirati Therapeutics Inc., with 170 participants planned, started 2026-05-06 and due to reach its primary completion in 2028-02-16. Interventions recorded: Adagrasib, Pembrolizumab, Cetuximab, Pemetrexed, Docetaxel and Irinotecan.
Shares Adagrasib, KRAS & RAS inhibitors, Pemetrexed, Bristol Myers Squibb and the tag pipeline.
Shares Adagrasib, KRAS & RAS inhibitors, Pemetrexed, Bristol Myers Squibb and the tag pipeline.
Shares Cetuximab, Pemetrexed, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Oxaliplatin, Pemetrexed, Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Cetuximab, Pemetrexed, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Docetaxel, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Oxaliplatin, Cetuximab, Pembrolizumab and the tag pipeline.